Sunday, December 05, 2021

NEWS

Argentina approves use of Sinopharm vaccine for minors

Argentina approves use of Sinopharm vaccine for minors

Buenos Aires, Oct 2 (Prensa Latina) The Argentine government announced today that it will begin to apply the Chinese Sinopharm anti-Covid-19 vaccine to minors between three and 11 years old, following its approval by the National Administration of Medicines, Food and Medical Technology (Anmat).
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The National Minister of Health, Carla Vizzotti, celebrated this good news and pointed out that the country will end 2021 with all its population over three years of age covered and protected, adding that they have enough to start this vaccination and complete the vaccination schedules.

Vizzotti explained that the vaccination schedules for children and teenagers will be completed with Sinopharm and Pfizer vaccines, between 21 and 28 days interval between the first and second application.

Anmat’s approval was granted after Phase 1 and 2 clinical trials, with studies in China and the United Arab Emirates. The Argentine president, Alberto Fernandez, pointed out in a message on Twitter, that the nation has a stock of almost 10 million doses of this vaccine to start immunizing Argentine children. One more reason to celebrate after so much collective effort, he said.

This southern nation has advanced since last June with accelerated steps in the immunization program and is approaching 70 million acquired doses of different vaccines to inoculate more than 45 million Argentinians.

mh/abo/ga/may

RELATED
ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.